|
🐜
|
An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities
35 auth.
E. B. Kaminsky,
V. Kaul,
J. Paschall,
D. Church,
B. Bunke,
Dawn Kunig,
D. Moreno-De-Luca,
A. Moreno-De-Luca,
J. Mulle,
S. Warren,
G. Richard,
J. Compton,
A. Fuller,
Troy J. Gliem,
Shuwen Huang,
...
M. Collinson,
Sarah J. Beal,
Todd Ackley,
D. Pickering,
D. Golden,
E. Aston,
H. Whitby,
S. Shetty,
M. Rossi,
M. K. Rudd,
S. South,
A. Brothman,
W. Sanger,
R. Iyer,
J. Crolla,
E. Thorland,
S. Aradhya,
David H. Ledbetter,
David H. Ledbetter,
C. Martin
|
8 |
2011 |
8
🐜
|
|
🐜
|
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.
16 auth.
Wen Zhou,
Ye Yang,
Jiliang Xia,
He Wang,
M. Salama,
W. Xiong,
Hongwei Xu,
S. Shetty,
Tiehua Chen,
Zhaoyang Zeng,
...
Lei Shi,
M. Zangari,
R. Miles,
D. Bearss,
G. Tricot,
F. Zhan
|
8 |
2013 |
8
🐜
|
|
🐜
|
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications
19 auth.
Andrew R. Morton,
Nergiz Dogan-Artun,
Zachary J. Faber,
G. Macleod,
C. Bartels,
Megan Piazza,
Kevin C. Allan,
S. Mack,
Xiuxing Wang,
Ryan C. Gimple,
...
Qiulian Wu,
B. Rubin,
S. Shetty,
S. Angers,
P. Dirks,
Richard C. Sallari,
M. Lupien,
J. Rich,
P. Scacheri
|
7 |
2019 |
7
🐜
|
|
🐜
|
Integrative Genomic and Transcriptomic Analysis Identified Candidate Genes Implicated in the Pathogenesis of Hepatosplenic T-Cell Lymphoma
15 auth.
J. Finalet Ferreiro,
Leila Rouhigharabaei,
H. Urbankova,
Jo-Anne van der Krogt,
L. Michaux,
S. Shetty,
L. Krenács,
T. Tousseyn,
P. de Paepe,
A. Uyttebroeck,
...
G. Verhoef,
T. Taghon,
P. Vandenberghe,
J. Cools,
I. Wlodarska
|
5 |
2014 |
5
🐜
|
|
🐜
|
Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative n
19 auth.
R. Kanagal-Shamanna,
Jennelle C Hodge,
Jennelle C Hodge,
Jennelle C Hodge,
T. Tucker,
S. Shetty,
A. Yenamandra,
A. Dixon-Mciver,
C. Bryke,
Emma Huxley,
...
P. Lennon,
G. Raca,
Xinjie Xu,
S. Jeffries,
F. Quintero-Rivera,
P. Greipp,
M. Slovak,
M. Iqbal,
M. Fang
|
4 |
2018 |
4
🐜
|
|
🐜
|
Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer
9 auth.
Alana R. Donaldson,
S. Shetty,
Zhen Wang,
Christine L. Rivera,
B. Portier,
G. Budd,
...
E. Downs‐Kelly,
Christopher P. Lanigan,
B. Calhoun
|
4 |
2017 |
4
🐜
|
|
🐜
|
PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin
12 auth.
S. Ondrejka,
A. Jegalian,
Annette S. Kim,
D. Chabot-Richards,
J. Giltnane,
David R. Czuchlewski,
...
S. Shetty,
M. Sekeres,
A. Yenamandra,
D. Head,
M. Jagasia,
E. Hsi
|
4 |
2014 |
4
🐜
|
|
🐬
|
Genetic aspects of human prion diseases
B. Appleby,
S. Shetty,
Mohamed Elkasaby
|
4 |
2022 |
4
🐬
|
|
🐜
|
NEK 2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
16 auth.
Wen Zhou,
Ye Yang,
Jiliang Xia,
He Wang,
M. Salama,
W. Xiong,
Hongwei Xu,
S. Shetty,
Tiehua Chen,
Zhaoyang Zeng,
...
Lei Shi,
M. Zangari,
R. Miles,
D. Bearss,
G. Tricot,
F. Zhan
|
4 |
2013 |
4
🐜
|
|
🐬
|
Cytogenetic and molecular diagnostic testing associated with prenatal and postnatal birth defects
S. Berisha,
S. Shetty,
T. Prior,
A. Mitchell
|
4 |
2020 |
4
🐬
|
